Skye Bioscience on Edge Ahead of High-Stakes Financial & Clinical Update

SAN DIEGO, CA – March 05, 2026 – All eyes in the biotech sector will be on Skye Bioscience (Nasdaq: SKYE) next week as the company prepares to release its full-year 2025 financial results and host a business update call on March 10. For the clinical-stage company, this is far more than a routine earnings announcement; it represents a critical inflection point that could define its future in the fiercely competitive multi-billion-dollar obesity drug market.

Investors and analysts will be parsing the numbers and commentary not just for financial health, but for crucial insights into the strategic path forward for its lead drug candidate, nimacimab. The call comes on the heels of a tumultuous year marked by soaring research costs, a setback in one clinical trial arm, and a simultaneous, promising breakthrough in another, creating a complex narrative of high risk and potentially high reward.

A Financial Tightrope Walk

The financial disclosures on March 10 will be scrutinized against a backdrop of escalating expenditures. As Skye has advanced nimacimab into a costly Phase 2a clinical trial, its spending has ballooned. The company's research and development expenses more than tripled in 2024, reaching $18.7 million, and that trend accelerated dramatically through 2025.

Quarterly reports from last year painted a stark picture of this cash burn. R&D costs hit $7.2 million in the first quarter of 2025, surged to $14.3 million in the second, and remained elevated at $9.4 million in the third. This spending drove significant net losses, including a $17.6 million loss in Q2 2025 alone. The stock market reacted accordingly, with Skye's share price falling by nearly 50% since late October 2025, reflecting investor anxiety over the mounting costs and the trial's mixed results.

While the company ended 2024 with a healthy cash position of $68.4 million and a projected runway to fund operations into 2027, the rapid burn rate in 2025 has raised concerns. The upcoming report will provide a definitive look at the year-end cash balance and any revisions to that runway, a key metric for a company without a commercial product.

Nimacimab's Pivotal Moment: A Tale of Two Trials

The financial story is inextricably linked to the clinical progress of nimacimab, a peripherally-acting CB1 inhibitor designed to treat obesity. The drug's Phase 2a trial, known as CBeyond™, has produced a dual narrative that encapsulates the volatility of drug development.

In October 2025, Skye announced that nimacimab as a monotherapy failed to meet its primary endpoint for weight loss compared to a placebo, a significant blow that contributed to the stock's decline. The company suggested the result may have been due to lower-than-expected drug exposure, leaving the door open for a potential comeback with higher dosing.

However, the story took a dramatic turn with the trial's other arm, which tested nimacimab in combination with the popular GLP-1 drug semaglutide (Wegovy®). Here, the results have been highly encouraging. Initial 26-week data showed the combination produced a statistically significant greater weight loss (-13.2%) compared to semaglutide alone (-10.25%).

More impressively, interim 52-week data released in February 2026 revealed the combination therapy led to a total weight loss of 22.3%, and the weight loss trajectory had not yet plateaued, suggesting further benefits are possible. Perhaps most compelling from a commercial standpoint, the combination demonstrated a remarkable durability advantage. During a 13-week follow-up period where patients were off the drugs, the nimacimab combination group regained less than half the weight compared to the group that had taken semaglutide alone. This potential to mitigate the well-known weight regain problem after stopping obesity medication could be a powerful differentiator.

Crucially, nimacimab has shown a strong safety profile, avoiding the neuropsychiatric side effects that doomed earlier-generation CB1 inhibitors that crossed the blood-brain barrier.

Navigating the Crowded Obesity Market

Skye Bioscience is not attempting to unseat the titans of the obesity market, Novo Nordisk and Eli Lilly, whose GLP-1 drugs Wegovy and Zepbound dominate the landscape. Instead, its strategy appears to be one of synergy. The promising combination data positions nimacimab as a complementary, add-on therapy that could enhance the efficacy and durability of existing market leaders.

This aligns perfectly with a broader industry shift. As the obesity market matures, focus is moving toward combination therapies to achieve greater weight loss, improve muscle preservation, and manage side effects. Major players are already exploring their own combinations, validating Skye's strategic direction. Nimacimab's unique mechanism as a peripheral CB1 inhibitor offers a novel pathway that is complementary, not redundant, to the incretin-based mechanisms of GLP-1 drugs.

Investors will be listening intently on the March 10 call for any updates on the company's strategy for advancing this combination therapy. Details on the design of a future Phase 2b or Phase 3 trial, regulatory feedback, and potential partnership discussions will be paramount. The business update will need to provide a clear and confident vision for how Skye plans to navigate this complex landscape and carve out a niche for nimacimab. The call will be a critical test of management's ability to convince the market that the promise of its combination therapy outweighs the risks highlighted by its rising costs and the setback in its monotherapy trial. For Skye Bioscience, the path forward will become significantly clearer after the market closes on March 10th.